Liposomal Delivery Systems for Improved Delivery of Docetaxel Against Prostate Cancer
Open Access
- 1 March 2026
- journal article
- review article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-29
Abstract
Generally, liposomes as a delivery system have been vastly designed for the delivery of therapeutic agents, to overcome various drawbacks, including resistance imposed to various conventional forms of these agents. They are significantly advantageous compared to other kinds of delivery systems because of their ability to deliver hydrophobic and hydrophilic therapeutic agents singly as monotherapy or combined as combinational therapy, owing to bilayer formation. Clinically, liposomes have been applied for delivery of therapeutic agents, with the aim of improving target-site-specificity and reducing toxicity to normal cells or tissues caused by chemotherapeutic drugs, which makes them relatively better options compared to the conventional forms of delivery system. Herein, a critical review which extensively discusses the various liposomal systems of delivery used for docetaxel (DTX) delivery against prostate cancer in the past decade, either alone as mono-therapeutical delivery or in combination with other therapeutic agents is presented. This review affirms to the potentials of employing liposomal systems of delivery for the effective targeted delivery of DTX against prostate cancer.Keywords
This publication has 153 references indexed in Scilit:
- RGD-decorated nanoliposomes for combined delivery of arsenic trioxide and curcumin to prostate cancer cellsNaunyn-Schmiedeberg's Archives of Pharmacology, 2023
- Identification of storage conditions stabilizing extracellular vesicles preparationsJournal of Extracellular Vesicles, 2022
- Multi‐Functional Liposome: A Powerful Theranostic Nano‐Platform Enhancing Photodynamic TherapyAdvanced Science, 2021
- Cancer burden of major cancers in China: A need for sustainable actionsCancer Communications, 2020
- Treatment of Metastatic Prostate Cancer in 2018JAMA Oncology, 2019
- The Roles of Tight Junctions and Claudin-1 in the Microbubble-Mediated Ultrasound-Induced Enhancement of Drug Concentrations in Rat ProstateThe Journal of Membrane Biology, 2015
- The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule‐Targeting Drugs in Prostate CancerJournal of Cellular Biochemistry, 2015
- A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignanciesCancer Chemotherapy and Pharmacology, 2012
- BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancerInternational Journal of Cancer, 2011
- Nanocarriers’ entry into the cell: relevance to drug deliveryCellular and Molecular Life Sciences, 2009